[Hepatitis C: therapeutic perspectives].
Trépo
Christian
C
Service de Médecine, Hôpital Général, Saint-Dizier.
D000956:Antigens, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002478:Cells, Cultured; D017326:Clinical Trials, Phase III as Topic; D016207:Cytokines / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005544:Forecasting; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000628:therapy* / Q000821:virology; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D011480:Protease Inhibitors / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D019562:Viral Load
D000956:Antigens, Viral; D000998:Antiviral Agents; D016207:Cytokines; D016898:Interferon-alpha; D011480:Protease Inhibitors; D012367:RNA, Viral; D012254:Ribavirin; D016899:Interferon-beta; D007372:Interferons